Noxopharm reports positive results for prostate cancer drug

By Jenni Spinner contact

- Last updated on GMT

(Dr_Microbe/iStock via Getty Images Plus)
(Dr_Microbe/iStock via Getty Images Plus)

Related tags: Cancer, Prostate cancer, Clinical trials, Drug development

The oncology drug development firm has announced 27% abscopal response in soft-tissue lesions with use of Veyonda and low-dose radiotherapy.

According to the company, its DARRT-1 clinical study ended with a 27% incidence of abscopal response in soft-tissue lesions, using a combination of its Veyonda cancer drug and low-dose radiotherapy. An abscopal response involves radiation directed at a single tumor, triggering shrinkage of tumors well outside of the field of radiation.

A growing use of immuno-oncology drugs in combination with radiotherapy reportedly has led to increasing reports of abscopal responses in various cancers, including lung, breast, and urogenital cancers and melanoma.

However, before now, no such reports have come from studies in prostate cancer with checkpoint inhibitors either alone or in combination with radiotherapy, leading to this cancer gaining a reputation as a “non-immunological” cancer.

The DARRT-1 study involved 15 men with mCRPC post-taxane and ADT therapy; these patients received Veyonda, an experimental sphingosine-1-phosphate inhibitor, along with a palliative dose of external beam radiotherapy to a single tumor, typically a lymph node cluster. An abscopal response was determined on the basis of scans of other nonirradiated soft tissue lesions.

Graham Kelly, executive chairman and CEO of Noxopharm, told Outsourcing-Pharma that the results of the trial are promising and informative.

While the mechanism behind it is yet to be fully explained, the growing evidence is that it has an immune basis​,” he said. “It appears to stem from use of a low dose of radiation (such as is commonly used in palliative therapy) which inflames rather than destroys the irradiated tumor. That inflammation then triggers an immune response that surges throughout the body, seeking out and destroying all other cancer cells​.”

Kelly added that to his knowledge, this study marks the first time that researchers have been successful in obtaining a meaningful abscopal response rate in prostate cancer.

Prostate cancer has developed a reputation as a cancer with poor immune responsiveness, but this outcome suggests that this isn’t the case when a drug with the appropriate effect on the immune system is used. Today’s result positions Veyonda at the forefront of this emerging area of oncology and suggests that we have an exciting new prospective treatment for end-stage prostate cancer​,” he said.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us

Products

View more

Webinars